Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OraQuick HCV Rapid Antibody Test · 1 trial · 1 indication
The study will measure the percentage of patients screened for Hepatitis C who are reactive by detecting HCV antibodies.
| Arm | Type | Description |
|---|---|---|
| High-Risk Patients | OTHER | OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations |
| Name | Type | Description |
|---|---|---|
| OraQuick HCV Rapid Antibody Test | DIAGNOSTIC_TEST | HCV Screening |
Inclusion Criteria: Subjects will be included in the study if the following criteria is met: 1. The subject must be an Opioid Substitution Treatment patient. 2. The subject must fall into another high-risk population for the HCV. Exclusion Criteria: Subjects may be excluded from the study if the...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
OraQuick HCV Rapid Antibody Test is used for Hepatitis C. It is an investigational diagnostic test being developed by Gilead Sciences, Inc. The test is intended to aid in the identification of Hepatitis C infection, as part of efforts to move from identification to elimination of the disease.
OraQuick HCV Rapid Antibody Test is developed by Gilead Sciences, Inc., which trades under the ticker GILD. The company is conducting clinical development of this diagnostic test for Hepatitis C.
OraQuick HCV Rapid Antibody Test is in Phase 1 clinical development. It is an investigational diagnostic test and has not been approved by regulatory authorities. One early Phase 1 trial has been completed.
OraQuick HCV Rapid Antibody Test has one completed clinical trial, NCT03195205, titled 'Identification to Elimination in HCV-Infected Individuals'. This early Phase 1 study enrolled 3,051 participants in the United States, with healthy volunteers included, and was an uncontrolled, non-randomized trial.
OraQuick HCV Rapid Antibody Test is not FDA approved. It is an investigational diagnostic test currently in Phase 1 clinical development. The completed trial NCT03195205 was an early Phase 1 study, and the test remains under investigation for Hepatitis C.